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ABSTRACT: Thrombospondin-2(TSP2)isamatricellularproteinwithincreasedexpressionduringgrowthand
regeneration. TSP2-null mice show accelerated dermal wound healing and enhanced bone formation. We
hypothesized that bone regeneration would be enhanced in the absence of TSP2. Closed, semistabilized
transverse fractures were created in the tibias of wildtype (WT) and TSP2-null mice. The fractures were
examined 5, 10, and 20 days after fracture using mCT, histology, immunohistochemistry, quantitative RT-PCR,
and torsional mechanical testing. Ten days after fracture, TSP2-null mice showed 30% more bone by mCT and
40% less cartilage by histology. Twenty days after fracture, TSP2-null mice showed reduced bone volume
fraction and BMD. Mice were examined 5 days after fracture during the stage of neovascularization and
mesenchymal cell inﬂux to determine a cellular explanation for the phenotype. TSP2-null mice showed in-
creased cell proliferation with no difference in apoptosis in the highly cellular fracture callus. Although mature
bone and cartilage is minimal 5 days after fracture, TSP2-null mice had reduced expression of collagen IIa and
Sox9 (chondrocyte differentiation markers) but increased expression of osteocalcin and osterix (osteoblast
differentiation markers). Importantly, TSP2-null mice had a 2-fold increase in vessel density that corresponded
witha reduction in vascular endothelial growth factor (VEGF) and Glut-1 (markers of hypoxia inducible factor
[HIF]-regulated transcription). Finally, by expressing TSP2 using adenovirus starting 3 days after fracture,
chondrogenesis was restored in TSP2-null mice. We hypothesize that TSP2 expressed by cells in the fracture
mesenchyme regulates callus vascularization. The increase in vascularity increases tissue oxemia and decreases
HIF;thus,undifferentiatedcells inthecallus developinto osteoblastsratherthanchondrocytes.This leads toan
alternative strategy for achieving fracture healing with reduced endochondral ossiﬁcation and enhanced
appositional bone formation. Controlling the ratio of cartilage to bone during fracture healing has important
implications for expediting healing or promoting regeneration in nonunions.
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INTRODUCTION
F
RACTURE HEALING IS characterized by deﬁned func-
tional and morphological stages. There is initial for-
mation of a hematoma and associated inﬂammatory cell
inﬂux, followed by vascularization and mesenchymal cell
expansion, chondrogenic and osteogenic differentiation,
endochondral and intramembranous bone formation, and
ﬁnally remodeling.
(1) At the cellular level, after the initial
inﬂammatory phase, processes that inﬂuence healing in-
clude mesenchymal cell migration, proliferation, differen-
tiation of the cells to either osteoblasts or chondrocytes,
and apoptosis of cells within the callus.
(1–4) Angiogenesis
and mechanical stability are likely crucial components
regulating these cellular events and the resultant callus
phenotype.
(5,6)
In the majority of clinical cases, fractures heal in an
uncomplicated manner; however, in severe fractures, and
in certain patient populations, such as diabetics and
smokers, there is delayed healing and an increased inci-
dence of nonunions. These cases are generally character-
ized by an increase in chondrogenesis and ﬁbrous tissue
development, with a resultant failure to undergo endo-
chondral ossiﬁcation. Absence of mechanical stability and
reduced vascularity are believed to be important predictors
of nonunion development and may result in dysregulation
of mesenchymal fate.
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1043A wide variety of secreted factors act locally within the
healing fracture to regulate vascularity, mesenchymal cell
function, and callus development. As examples, vascular
endothelial growth factor (VEGF),
(5,7) matrix metal-
loproteinase 9 (MMP9),
(8) bone morphogenetic protein 3
(BMP-3),
(9) and placental growth factor
(10) have all been
shown to regulate cell differentiation, callus size, and heal-
ing. In addition, extracellular matrix (ECM) proteins, in-
cluding collagen
(11) and osteopontin,
(12) have been shown to
affect fracture phenotype.
Thrombospondin-2 (TSP2) is another ECM protein that
could play a role in regulating fracture healing. TSP2 is a
secreted glycoprotein encoded by the Thbs2 gene and was
the second member discovered in the family of ﬁve throm-
bospondin proteins.
(13,14) TSP2 is a matricellular protein
that modulates cell–matrix interactions and is highly ex-
pressed in developing and healing tissues.
(15) Mice with a
targeted disruption of the Thbs2 gene (TSP2-null) exhibit a
complex phenotype. In the skeleton, TSP2-null mice possess
greater cortical bone thickness as a result of an increase in
endocortical bone formation.
(16) The increase in bone for-
mation is associated with an increase in mesenchymal pro-
genitor (marrow stromal cell) number, as determined by
colony forming unit-ﬁbroblast (CFU-F), and stromal cells
lacking TSP2 show an increase in proliferation. TSP2-null
mice also exhibit atypical bone formation in response to
mechanical loading.
(17)
In addition to a pronounced bone phenotype, TSP2-null
mice show altered soft tissue wound healing
(18) and en-
hanced recovery to ischemic injury of skeletal muscle
(19);
both occur secondary to an increase in vascularity. TSP2
directly inhibits endothelial cell growth,
(20,21) and exoge-
nously delivered TSP2 can regulate angiogenesis in vivo,
particularly in association with cancer.
(22,23)
Considering the bone phenotype and the response
to cutaneous wounding and muscle ischemia in the absence
of TSP2, we hypothesized that TSP2-null mice would
exhibit accelerated fracture healing. To test this hypothe-
sis, we used the TSP2-null mouse and its coisogenic wild-
type mouse in an in vivo model of fracture healing. We
show here that the fracture callus in the TSP2-null mouse
exhibits greater vascularity and cell proliferation, en-
hanced intramembranous bone formation, and reduced
endochondral ossiﬁcation compared with WT mice. The
absence of TSP2 expedites callus bone formation by
altering the differentiation fate of mesenchymal cells,
shifting differentiation toward osteoblasts instead of
chondrocytes. When TSP2 is delivered to calluses after
fracture using adenovirus, a WT chondrogenic phenotype
is restored.
MATERIALS AND METHODS
Mice
All procedures were approved by the Institutional Ani-
mal Care and Use Committee. The mice used had a tar-
geted disruption of the Thbs2 gene, which encodes the
thrombospondin-2 protein (TSP2-null).
(24) Coisogenic WT
129/SvJ mice were used for comparison.
Surgical procedure
We created closed, transverse fractures in both tibias of
63- to 70-day-old mice using methods similar to those
described previously by Hiltunen et al.
(25) Brieﬂy, mice
were anesthetized for all surgical procedures using isoﬂu-
rane (Aerrane; Baxter, Deerﬁeld, IL, USA), and 0.05 mg/
kg of butorphanol tartrate (Torbugesic-SA; Fort Dodge
Animal Health, Fort Dodge, IA, USA) analgesic was ad-
ministered subcutaneously shortly after anesthetic induc-
tion. Both legs were prepared for aseptic surgery. Mice
were placed in dorsal recumbency on microwaveable
heating pads for the duration of anesthesia to maintain
normal body temperature. The stiﬂe joint of the right leg
was ﬂexed, and a small incision was made just medial to the
tibial tuberosity. A 26-gauge hypodermic needle was used
to bore a hole in the cortex of the medial aspect of the tibial
tuberosity, slightly distal to the stiﬂe joint. A sterile,
0.009-in-diameter, stainless steel pin was inserted into the
created hole and inserted down the length of the tibia in
the intramedullary canal until resistance was felt, indicat-
ing full insertion. This served as an intramedullary pin
that would provide stability at the fracture site. This pro-
cedure was repeated for the left leg. After pin insertion,
the pins were cut to be ﬂush with the cortex, and the skin
defect was closed using tissue adhesive (Nexaband; Abbott
Laboratories).
Fractures were created in both legs using a custom-made
device that uses a sliding weight and guillotine mechanism.
This device produces consistent controlled displacement,
high-energy impact force sufﬁcient to induce fractures in
mouse tibias. Mice were placed in sternal recumbency, and
each leg was individually placed in the guillotine and
fractured. Whole body radiographs were generated using a
microradiography system (Faxitron, Wheeling, IL, USA)
to verify pin placementand fracture gap location. Fractures
analyzed were typically midshaft, simple, transverse frac-
tures, although occasionally fracture occurred in the distal
one third of the tibia. Tape ‘‘splints’’ were placed on both
tibias to provide initial rotational stability to the fracture
region for the ﬁrst 48 h.
Mice recovered after the procedure under heat lamps.
Moistened food was placed on the cage bottom, and water
was provided ad libitum. Mice were typically ambulatory
within 1 h after surgery and were observed eating within a
few hours. Mice were maintained in a cage with wireless
tops to reduce climbing activity. No mortality was observed
throughout the course of this study.
Tissue harvest and preparation
At harvest, all animals were anesthetized with isoﬂurane
gas anesthetic and humanely killed by cervical dislocation.
Right tibias were carefully dissected, the intramedullary
pins were removed, and the tibias were placed in 4% par-
aformaldehyde for 24 h, decalciﬁed in formic acid for 12 h,
and transferred to 70% ethanol until further processing for
histology or immunohistochemistry (IHC). Left tibias were
similarly dissected, wrapped in saline-soaked gauze, and
placed in storage at –208C until mCT scanning and torsional
mechanical testing could be performed.
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Sampleswerescanned usinganeXploreLocusSPmicroCT
system (GE Healthcare Preclinical Imaging, London,
Ontario, Canada) and reconstructed at an 18-mm isotropic
voxel size using the Feldkamp cone beam algorithm. A
custom software analysis procedure was speciﬁcally de-
veloped to quantify the callus properties on these images
using Microview (v 2.1.2 Advanced Bone Application; GE
Healthcare Preclinical Imaging) similar to that described
by Den Boer et al.
(26) First, the image was reoriented so
that the anterior-posterior and longitudinal axes were
aligned with the principal image axes. In the second step,
three independent reviewers scrolled through the image
planes and measured the maximum callus width using a
line that bisected the middle of the marrow cavity as well as
the maximum callus length on the anterior side of the bone
(Fig. 1A). The measurements for maximum callus width
and maximum callus length were averaged across the three
reviewers, and the average length was used to isolate the
callus from the image of the entire bone (Fig. 1B). Next,
the callus and cortical bone sections were manually seg-
mented using a series of user-deﬁned points with spline
interpolation between these points (Fig. 1C). The points
for cortical bone boundary were chosen on slices of the
image not more than 30 CT slices (0.540 mm) apart, and
spline interpolation was used to deﬁne the points in be-
tween. These points were reviewed and modiﬁed, and a
reinterpolation was performed in an iterative process. A
similar process was used to deﬁne the callus boundary.
Next, a single point within the cortical region of interest
was used to initiate a region-growing algorithm that de-
tected the cortical bone by ﬁnding all connected voxels
over a simple global threshold. This region-growing algo-
rithm was conﬁned by the cortical region of interest to
ensure that mature bone within the callus, particularly near
the proximal and distal ends, was not included in the cor-
tical bone measurements (Fig. 1D). The cortical bone
voxels were removed from the image so that it did not bias
any measurements (Fig. 1E). Last, the region of interest
surrounding the callus was identiﬁed (Fig. 1F), a global
threshold was applied, and the callus volume, bone volume
fraction, BMD, BMC, tissue mineral content (TMC), and
tissue mineral density were calculated (TMD). Bone min-
eral measurements represent the mineral contained in the
entire callus volume. Tissue mineral measurements repre-
sent the mineral contained within the volume deﬁned as
bone (Fig. 1G).
FIG. 1. Quantiﬁcation of callus length, total volume, and bone volume using mCT. (A) Anterior callus length was measured in all
specimens (white line). (B) Next, using the maximum callus length, the callus was cropped from the image. (C) Splines were separately
traced around the cortical bone and callus. (D) The spline around the cortical bone served as a conﬁning region for a region growing
algorithm based on a global threshold (the image shown is binarized at this threshold) that ﬁnds all connected cortical bone voxels (the
cortical bone that is detected is shown in grey); callus bone is white. (E) The cortical bone voxels are removed from the image by region
blanking (gray voxels in (D) becomes black in (E). (F) A ﬁnal 3D isosurface rendering showing the callus and the region used to analyze
the bone that it contains. (G) A histogramof the grayscale values was plotted for callus bone in every specimen. The curves shown are the
average of all mice within a particular treatment group and time point. The curve for TSP2-null mice is higher after 10 days, indicating
that more bone is present at this time point. After 20 days, the curve for TSP2-null mice is lower, indicating that these mice have less bone
in the callus. The shaded region indicates the region used to separate mineralized voxels from unmineralized voxels; the shaded region is
usedfor TMCandTMDcalculations,whereastheentirehistogramis usedforBMCandBMDcalculations.Thedrop-offinthehistogram
near a grayscale value of 3500 HU is because of the removal of dense bone (which was predominantly residual cortical bone from the
original cortices) from the image.
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Tibias were secured in brass pots using a low melting
temperature Cerro Alloy (McMaster Carr, Chicago,IL,USA)
and mounted into a custom torsion testing device. This
torsion tester was equipped with a 50 in.oz. reaction torque
sensor (Model 2105–50; Eaton, Troy, MI, USA) and an
RVDT (Model R30A; Lucas Control Systems, Hampton,
VA, USA) for torque and angular displacement measure-
ments, respectively. Raw torque data were conditioned
with a strain gage ampliﬁer (2100; Measurements Group,
Raleigh, NC, USA), and angular displacement was condi-
tioned with an LVDT ampliﬁer (DTR-451; Lucas Control
Systems) before collection. This device was interfaced with
LabVIEW (v 7.0; National Instruments, Austin, TX, USA)
for data collection and controlled using a custom program
that interfaced using a data acquisition system (NI PCI-
6251; National Instruments). The bones were tested at a
constant displacement rate of 0.58/s until failure while be-
ing maintained moist at room temperature. Data were
sampled at 1000 Hz at a displacement rate of 0.58/s and
stored for analysis. Analysis was performed using a custom
MATLAB (v 7.0.1; The Mathworks, Natick, MA, USA)
script. In this script, the torque data were ﬁltered with a
third-order Savitzky-Golay FIR smoothing ﬁlter with a 0.5-
s window before analysis to remove noise. The stiffness was
calculated based on a linear regression on the torque-dis-
placement data in a user-selected region, and the script
automated calculations for torque at failure, angular dis-
placement at failure, and energy to failure.
Safranin-O histology
Safranin-O staining was performed on right mouse tibias
that were parafﬁn embedded and serially sectioned (7 mm).
Brieﬂy, slides were deparafﬁnized, rehydrated, and ex-
posed to 0.3% Fast Green FCF (Fisher, Pittsburgh, PA,
USA). Slides were rinsed in 1% acetic acid (Fisher), im-
mersed in 5.45% Safranin-O (Fisher), rinsed in dH2O,
dehydrated, mounted using Permount (Biomeda, Foster
City, CA, USA), and visualized using a microscope. These
samples were used for measuring total callus area, chon-
drocyte area (i.e., Safranin-O–positive area), and area of
woven bone. Hypertrophic chondrocyte areas were deﬁned
based on the characteristic appearance of those chondrocytes.
Peroxidase-based IHC
Right mouse tibias were parafﬁn embedded and serially
sectioned (7 mm). Sections were next deparafﬁnized,
rehydrated, immersed in heated citrate buffer, and incu-
bated with 3% H202 in PBS. Slides were blocked and ex-
posed to the respective primary antibody: collagen type IIa
(graciously gifted from Dr. Linda Sandell, Washington
University), proliferating cell nuclear antigen (PCNA;
Chemicon International, Temecula, CA, USA), and von
Willebrand’s factor (vWF; Dako, Carpinteria, CA, USA).
After treatment with the primary antibody (collagen type
IIa, 1:5000; PCNA, 1:1500; vWF, 1:400), sections were
treated with biotin-conjugated secondary antibody (for
collagen type IIa, 1:150; for PCNA, 1:400; for vWF, 1:500;
for PCNA: Jackson Immunoresearch, West Grove, PA,
USA; for collagen type IIa/vWF: Vector Laboratories,
Burlingame, CA, USA). After secondary antibody treat-
ment, slides were treated with streptavidin-conjugated
horseradish peroxidase (HRP; StriAviGen Super Sensitive
Label Antibody; Biogenex Laboratories, San Ramon, CA,
USA) and diaminobenzidine (Dako). Slides were coun-
terstained with Gill’s hematoxylin, dehydrated, mounted
using Permount (Biomeda, Foster City, CA, USA), and
visualized using a microscope. Mouse spleen and heart
tissue were used as control tissues for vWF, and mouse
testicular tissue was used as positive and negative control
tissue for PCNA.
Fluorescent immunolocalization
Expression of b-galactosidase, osteocalcin (OCN),
osterix (OSX), Sox9, TSP2, and VEGFA was assessed by
immunoﬂuorescence in serially sectioned (7 mm) parafﬁn-
embedded fractured tibias samples (b-galactosidase/OSX/
Sox9; Abcam, Cambridge, MA, USA; OCN: Takara, Shiga,
Japan; TSP2: BD Transduction Laboratories, San Jose,
CA, USA; VEGFA: Novus, Littleton, CO, USA). After
treatment with the primary antibody (b-galactosidase,
1:250; OCN/OSX/Sox9/TSP2/VEGFA, 1:100), sections
were treated with Alexaﬂuor 594–labeled secondary anti-
bodies (1:200; Molecular Probes, Carlsbad, CA, USA),
mounted with Vectashield containing DAPI (Vector Lab-
oratories, Burlingame, CA, USA), and visualized with a
ﬂuorescent microscope.
TUNEL assay
After tissue rehydration, slides were placed in 958C cit-
rate buffer for 20 min and, after removal, allowed to cool
for 20 min. Next, slides were incubated for 15 min in 3%
H2O2 and incubated for 2 h with the terminal transferase
(TdT; Roche, Basel, Switzerland) and biotin-conjugated
16-dUTP (Roche) reaction mixture. Incubation with
streptavidin-conjugated HRP and DAB chromogen and
hematoxylin counterstain were carried out in the same
manner as was performed for IHC. Mouse testicular tissue
was used for controls. Positive control tissues were incu-
bated with DNase. Negative controls used testicular tissue
without the TdT and or without the 16-dUTP. All control
tissues were run in parallel with samples.
Adenoviral delivery
TSP2 and control b-galactosidase adenovirus were gener-
ated by the University of Michigan Vector Core. TSP2-null
mice tibias were fractured, and at day 3 after fracture, 10 mlo f
13 10
8TSP2adenovirusorLacZ control adenovirusparticles
was injected into the fracture site using Luer Tip Hamilton
syringes. Each mouse was injected with LacZ on one side and
TSP2 on the contralateral side. The mice were given 10 days
to heal after fracture and killed. Tissue was collected and
processed as described in the IHC methods and stained ac-
cording to the Safranin-O protocol detailed earlier.
Histomorphometry
Total callus area, Safranin-O–positive area, hypertrophic
cell area, woven bone area, and the area of cells showing
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magniﬁcation using Bioquant Image Analysis software
(Bioquant Image Analysis, Nashville, TN, USA). Using the
manual measure function of this software, we identiﬁed
appropriate areas and outlined them. Three tissue sections
per slide were measured, and the average was calculated.
For the quantiﬁcation of PCNA and TUNEL labeling,
we used a method similar to that described by Li et al.
(2)
Brieﬂy, the lengthof the fracture callus wasmeasured using
the Bioquant software at 34 magniﬁcation. Within the
proximal, middle, and distal third of the fracture callus, the
total number of positive and negative cells was measured in
three ﬁelds of view at 363 magniﬁcation for a total of nine
ﬁelds per tissue section. These measurements were re-
peated on three tissue sections on the same slide for a total
of 27 measures per sample. The average number of positive
cells over all ﬁelds measured represents the percentage of
positive cells within the fracture callus.
Total OCN, OSX, Sox9, and VEGFA areas were quan-
tiﬁed, at 3200 magniﬁcation, using the SigmaScan Pro 5
software (Aspire Software International, Ashburn, VA,
USA). Using the manual measure function of this software,
positive areas within the total callus were identiﬁed and
outlined. Three tissue sections per slide were measured,
and the average was calculated.
Time course gene expression analysis for TSP2
WT (C57/B6) mice were placed in groups (n = 4 per time
point) and given either 0 (no fracture), 5, 7, 10, 14, 18, or 21
days to heal and were subsequently killed. Fracture cal-
luses were carefully dissected and immediately snap frozen
in a liquid nitrogen bath. Frozen tissue samples were ho-
mogenized using a liquid nitrogen-cooled mortar and pes-
tle apparatus, and mRNA was puriﬁed using TRIzol (In-
vitrogen, Carlsbad, CA, USA). Single-strand cDNA was
synthesized from exactly 0.5 mg mRNA from each sample.
Speciﬁc primers for b-actin (internal control) and TSP2
were used for real-time PCR analysis (Corbett Research,
Carlsbad, CA, USA). Samples were denatured at 948C for
20 s, annealed at 588C for 30 s, and ampliﬁed at 728C for 30
s for a total of 30 cycles. C(t) results were compared with b-
actin expression and fold-change (relative to day 9 non-
fracture controls) was determined using previously de-
scribed methodology.
(22)
QPCR gene expression analysis for day 5 samples
Fracture calluses were extracted and macerated using a
Tissue Tearor (Biospec Products, Bartlesville, OK, USA).
RNA was isolated using the Qiagen RNeasy Mini kit
(Qiagen, Valencia, CA, USA). RNA yield was determined
spectrophotometrically, and integrity was conﬁrmed by gel
electrophoresis. cDNA synthesis was done as described
previously. The expression levels of the following genes
were determined using a 7500 Fast Real-Time System
machine (Applied Biosystems, Foster City, CA, USA):
collagen type IIa, OCN, OSX, Runx2, Sox9, VEGFA, b-
actin, and laminA. Taqman Gene Expression Assays
(Applied Biosystems) were used for OSX, Runx2, Sox9,
VEGFA, and LaminA (internal control), and the following
primers were used for collagen type IIa, OCN, and b-actin
(internal control) with Power SYBR Green (Applied
Biosystems) [Forward (F)/Reverse(R)]:
collagen type IIa: (F)GGCTCCCAGAACATCACCTA/
(R)TCGGCCCTCATCTCTACATC
osteocalcin: (F)CGCTCTGTCTCTCTGACCTC/(R)TCA
CAAGCAGGGTTAAGCTC
b-actin: (F)AAGAGCTATGAGCTGCCTGA/(R)TGGC
ATAGAGGTCTTTACGG
FIG. 2. TSP2 expression is increased during early bone regen-
eration. (A) TSP2 gene expression was characterized at 0, 5, 7,
10, 14, 18, and 21 days after fracture and fold-change in expres-
sion was compared with nonfractured bone. *Values are not
signiﬁcantly different (p < 0.05) from each other, but are signif-
icantly different from all other values, with the exception that the
difference between day 14 and day 7 is not signiﬁcant;
†signiﬁcantly different (p < 0.05) from all other values except day
7;
‡signiﬁcantly different from all values with the exception day 0.
Bars represent mean and error bars represent SD. n =3 .( B )
Composite image showing TSP2 detection in vivo using immu-
noﬂuorescence (magniﬁcation bar = 100 mm). Red indicates
areas of TSP2 expression, and cell nuclei are shown in blue (B,
bone; C, callus; M, marrow).
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double DCT method, and proper amplicon formation was
conﬁrmed by melt curve analysis.
Statistical analysis
One-way ANOVA was used to assess statistical signiﬁ-
cance between WT and TSP2-null samples at each time
point. Results for the temporal analysis of gene expression
were analyzed using one-way ANOVA with Tukey post-
hoc analysis. Animal numbers for each experiment varied
and are indicated in the ﬁgure legends.
RESULTS
TSP2 is highly expressed in 5-day fracture callus
Previous research has shown that TSP2 is primarily
expressed by mesenchymal cells and in mesenchymal ori-
gin tissues but is not expressed by hematopoietic cells or
endothelial cells.
(20,27,28) TSP2 expression was upregulated
in response to fracture (Fig. 2A). Levels of TSP2 increased
100-fold in day 5 fractures relative to unfractured day 0
controlsand subsequentlydeclined until day18 when levels
normalized. Immunolocalization showed that TSP2 was
expressed broadly in the 5-day fractures. TSP2 is expressed
highest in the mesenchyme associated with/around the
fracture site (Fig. 2B). Fluorescence detection was rela-
tively low in day 10 and day 20 calluses, but a positive signal
was present relative to the negative control (TSP2-null).
TSP2-null mice show alterations in callus
morphology
To determine whether an absence of TSP2 would alter
fracture healing, we used high-resolution mCT to precisely
measure the callus volume, anterior callus length, maxi-
mum width, bone volume, mineral content, and mineral
density of healing tibial fractures in TSP2-null mice at 10
and 20 days after fracture (dpf) (Table 1). Because of the
low bone content of the callus, day 5 fractures could not be
evaluated by mCT. Ten days after fracture, callus bone
volume, BVF, BMC, BMD, and TMC in TSP2-null mice
were signiﬁcantly greater compared with the callus in WT
mice. These data, considered in conjunction with a voxel
Hounsﬁeld distribution histogram (Fig. 1G), showed that
the TSP2-null mice have more newly formed bone in the
callus than WT. Callus shape is also different. Speciﬁcally,
TSP2-null fractures show a greater callus length to width
ratio because of a reduction in length. TMD, which reﬂects
the density of the mineral in voxels identiﬁed as bone, was
signiﬁcantly less in the TSP2-null mice than in the WT mice
(Table 1). At 20 dpf, the callus volume, width, and
width:length ratio were similar between the genotypes.
However, callus length was still slightly reduced in the
TSP2-null mice. Surprisingly, BVF and BMD were signif-
icantly less in the TSP2-null mice after 20 days of healing
(Table 1; Fig. 1G).
To evaluate the functional consequence of the alterations
in bone and callus geometry in the absence of TSP2, tibias
TABLE 1. mCT Parameters of 10- and 20-Day Harvested Fractures
Measured parameter
10 days after fracture 20 days after fracture
WT (n = 13) TSP2-null (n = 11) WT (n = 10) TSP2-null (n = 11)
Length (mm) 6.58 (0.58) 5.83 (0.88)* 6.08 (0.42) 5.64 (0.66)
Width (mm) 2.75 (0.53) 2.89 (0.33) 2.65 (0.29) 2.59 (0.43)
Length:width ratio 0.42 (0.07) 0.50 (0.08)* 0.44 (0.07) 0.46 (0.07)
Total volume (mm
3) 19.54 (5.43) 22.48 (5.52) 19.40 (4.70) 20.32 (7.89)
BMC (mg) 3.51 (0.81) 4.52 (1.00)* 6.81 (1.60) 6.12 (1.76)
BMD (mg/ml) 182.53 (22.83) 202.54 (14.22)* 352.2 (22.79) 312.48 (44.57)*
Bone volume (mm
3) 3.71 (0.79) 4.92 (0.92)* 9.71 (2.20) 7.61 (2.04)
Bone volume fraction (%) 19.56 (3.65) 22.38 (3.35)
† 47.55 (5.24) 39.09 (6.25)*
Tissue mineral content (mg) 1.96 (0.38) 2.46 (0.49)* 5.57 (1.26) 4.80 (1.21)
Tissue mineral density (mg/ml) 530.49 (22.39) 500.34 (22.58)* 610.75 (33.20) 632.29 (30.98)
For statistical analysis, WT was compared with TSP2-null at either 10 or 20 days.
* p < 0.05.
† p = 0.06.
TABLE 2. Mechanical Properties of Fractures at 10 and 20 Days
Measured parameter
10 days after fracture 20 days after fracture
WT (n = 16) TSP2-null (n = 9) WT (n = 11) TSP2-null (n = 13)
Stiffness (N-mm/8) 0.05 (0.03) 0.06 (0.03) 0.35 (0.16) 0.34 (0.12)
Displacement (8) 45.60 (23.33) 49.00 (22.60) 35.16 (9.04) 29.5 (7.00)
Failure torque (N-mm) 1.62 (1.01) 2.12 (0.69) 9.72 (2.96) 8.37 (2.09)
Energy (N-mm*deg) 63.32 (51.32) 63.18 (47.30) 194.34 (74.28) 129.58 (48.21)*
For statistical analysis, WT was compared with TSP2-null at either 10 or 20 days.
* p < 0.05.
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low level of bone in the calluses of day 5 fractures, me-
chanical testing was not performed for these specimens.
Despite the increase in bone in the TSP2-null fracture cal-
luses at 10 dpf, there were not any signiﬁcant differences in
the torsional mechanical properties (Table 2). However, in
evaluating calluses 20 dpf, the energy to failure of the TSP2-
null calluses was signiﬁcantly decreased.
TSP2-null mice show a reduction in callus cartilage
We next evaluated fractures histologically to gain more
insight into the alterations in callus geometry and bone
content. Qualitatively, there was an obvious reduction in
the amount of cartilage in the TSP2-null mice at 10 dpf
(Fig. 3A). When we measured the amount of safranin-
O–positive cartilage using histomorphometry, the results
indicated that fractures in the TSP2-null animals had 40%
less cartilage (Fig. 3B). However, there was no difference
in the percentage of cartilage that was composed of hy-
pertrophic chondrocytes between the genotypes, suggest-
ing that the progression of cartilage maturation is similar.
At day 20, both WT and TSP2-null specimens had very
little cartilage. However, even at this time point, all of the
WT samples showed some small amount of cartilage,
whereas only one half of the TSP2-null specimens con-
tained cartilage (results not shown).
TSP2-null fractures show differences in callus size
and mesenchymal cell proliferation
Because the fractures of the WT and TSP2-null mice
already showed substantial changes by day 10 and we were
unable to evaluate day 5 fractures using mCT and mechan-
ical testing, we performed a comprehensive histological
and gene expression evaluation of fractures at day 5.
The fracture calluses in both the WT and TSP2-null mice
at 5 dpf were composed of undifferentiated mesenchy-
mal cells without appreciable bone or cartilage, but TSP2-
null fractures had a 20% greater area than WT (Figs. 4A
and 4B). Previous work has shown that TSP2 regulates
mesenchymal cell proliferation,
(16) and additional studies
have shown that thrombospondins can regulate apopto-
sis.
(29) Recognizing the importance of these processes in
the size of the developing callus, PCNA was used to eval-
uate mesenchymal cell proliferation, and TUNEL staining
was used to evaluate mesenchymal cell apoptosis. Calluses
from TSP2-null mice showed a 25% increase in PCNA
positive cells compared with those from WT mice (Figs. 4C
and 4E), but levels of apoptosis were equivalent (Figs. 4D
and 4E).
TSP2-null mice show decreased chondrogenic
differentiation and increased osteoblast
differentiation at day 5
There is no safranin-O–positive mature cartilage at 5 dpf
(Fig. 4A), but mesenchymal cells are beginning to undergo
chondrogenic differentiation. Using IHC, we measured the
amount of collagen type IIa and Sox9 expression as indi-
cators of early chondrocyte differentiation. Both type IIa
collagen and Sox9 expression peak around 5 dpf and di-
minish with cartilage maturation and hypertrophy.
(30,31)
The TSP2-null mice had signiﬁcantly less type IIa collagen–
positive area (Figs. 5A and 5B) and reduced expression of
Sox9 (Figs. 5C and 5D). To examine osteoblast differen-
tiation of the callus mesenchymal cells, we evaluated os-
teocalcin and osterix expression. Expression of both oste-
ocalcin (Figs. 5E and 5F) and osterix was signiﬁcantly
increased in TSP2-null fractures (Figs. 5G and 5H). We
also harvested total RNA from day 5 fractures and found
that the expression of osteocalcin RNA was signiﬁcantly
increased in the TSP2-null mice, whereas type II collagen
RNA was signiﬁcantly decreased(Fig. 5I). These data show
that TSP2-null mice have a reduction in chondrogenic
differentiation and enhanced osteoblast differentiation.
TSP2-null fractures show enhanced vascularity and a
reduction in markers of hypoxia-inducible factor
activity
Thrombospondins are potent regulators of angiogenesis,
and previous work has shown that TSP2-null mice show
FIG. 3. TSP2-null mice have signiﬁcantly less callus cartilage
than WT mice 10 days after fracture. (A) Safranin-O–stained
sections of midcallus showing cartilage areas (dark staining) in WT
and TSP2-null mice (magniﬁcation bar = 500 mm). (B) The per-
centage of the callus that is cartilage and the percent of cartilage
that is hypertrophic was determined using Bioquantimage analysis
system. Values are mean ± SE of WT (n = 14) and TSP2-null (n =
13) mice. *Signiﬁcantly different from WT (p < 0.05).
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(18) and enhanced recov-
e r yt oi s c h e m i ai nm u s c l e ,
(19) caused in part by enhanced
vascularity. Because the development of vascularity in the
callus is an important part of the fracture healing response,
vWF expression within the callus was used to determine
vessel density. Importantly, the number of whole blood
vessels within the callus that could be identiﬁed by their
labeling with anti-vWF antibody and the presence of a dis-
tinct lumen was 2-fold greater in the TSP2-null mice com-
pared with the WT mice at 5 dpf (Figs. 6A and 6B).
Because hypoxia-inducible factor (HIF) activity is recog-
nized positive regulator of chondrogenic differentiation,
(32)
we hypothesized that the increased vascularity in TSP2-
null mice would result in reduced hypoxia and lead to a
reduction in HIF activity. As a surrogate of HIF activ-
ity,
(33) we evaluated VEGFA expression using IHC and
quantitative RT-PCR and Glut-1 expression using quanti-
tative RT-PCR. VEGF expression was reduced in tissue
sections (Figs. 6C and 6D), and both Glut-1 and VEGFA
were decreased in TSP2-null fractures as measured by
qPCR (Fig. 6E).
Delivery of TSP2 adenovirus to TSP2-null fractures
increases chondrogenesis in 10-day fractures
To examine the temporal requirement of TSP2 to in-
ﬂuence fracture cell fate, TSP2 was delivered to fractures in
TSP2-null mice 3 dpf during the time of mesenchymal cell
inﬂux and neovascularization, and fractures were evalu-
ated using histology at day 10. Adenovirus delivered in
this manner was effectively taken up by the cells of the
mesenchymal callus (Fig. 7A). TSP2 overexpression re-
sulted in enhanced callus cartilage in TSP2-null mice
(Fig. 7B).
DISCUSSION
Previous work has shown that TSP2 acts to regulates the
time course of dermal wound healing
(18) and expedites re-
covery to muscle ischemia.
(19) In this study, we found that
TSP2 alters the temporal progression of bone regeneration.
Ten days after fracture, TSP2-null mice have substantially
less cartilage and an increase in the amount of bone. At day
5 when chondrogenic differentiation is just beginning, but
there is no mature cartilage, chondrocyte markers are re-
duced and osteoblast markers are increased in TSP2-null
mice. Thus, whereas undifferentiated mesenchymal cells in
the central portion of the callus are undergoing differenti-
ation to chondrocytes in WT mice, in TSP2-null mice, fewer
cells become chondrocytes and more become osteoblasts.
Importantly, the ratio of total cartilage that is hypertrophic
(mature) cartilage in WT and TSP2-null mice is equivalent
FIG. 4. TSP2-null fractures 5 days after fracture show increased callus size and enhanced mesenchymal cell proliferation. (A) Safranin-
O–strained tissues showing appearance of provisional callus but an absence of mature cartilage at 5 dpf (magniﬁcation bar = 500 mm).
Note that Safranin-O staining at this time is generally nonspeciﬁc staining of provisional matrix and not bright red relative to the
appearance of cartilage in Fig. 3. (B) Area of the fracture callus determined using histomorphometry is slightly greater in TSP2-null mice
compared with WT. (C) PCNA expression was examined to evaluate the proliferation of mesenchymal cells. Brown nuclei are PCNA
positive (magniﬁcation bar = 100 mm). (D) TUNEL was used to evaluate cells undergoing apoptosis. Brown nuclei are TUNEL
+
(magniﬁcation bar = 100 mm). (E) PCNA staining is greater in the fracture callus of TSP2-null mice compared with WT mice, but there is
no difference in TUNEL. Values are mean ± SE of WT (n = 13) and TSP2-null (n = 12) mice. *Signiﬁcantly different from WT (p < 0.05).
1050 TAYLOR ET AL.at day 10, suggesting that chondrogenic maturation is nor-
mal in the callus of TSP2-null mice.
In the fracture gap, undifferentiated mesenchymal cells
that contribute to healing are derived from periosteum,
endosteum, surrounding fascia and muscle, and marrow.
These mesenchymal cells differentiate to become either
osteoblasts orchondrocytes or they undergoapoptosis. The
osteoblasts participate in direct intramembranous bone
formation, whereas the chondrocytes form cartilage that
will subsequently undergo endochondral bone formation.
The molecular mechanisms dictating the fate decision of
callus mesenchyme in regenerating bone remains unclear.
Whereas a variety of possible factors may contribute to this
fate decision, vascularity and oxygen tension in the fracture
gap likely plays a prominent role. Hypoxia and the resul-
tant induction of Hif1a has been shown to be prochon-
drogenic.
(32,34,35) Indeed, in our study, we concluded that
the dominant mechanistic explanation for the shift in me-
senchymal cell fate in WT and TSP2-null mice is that a
substantial increase in vascular density in TSP2-null mice
alters tissue oxygen tension. Enhanced oxemia promotes
the differentiation of bipotent cells to become osteoblasts
rather than chondrocytes.
Thrombospondins have been extensively studied as en-
dogenous inhibitors of angiogenesis for 20 yr.
(36–38) Mice
lacking TSP1 and TSP2 show increases in angiogenesis,
(24)
FIG. 5. The fracture callus of TSP2-null
mice 5 days after fracture has reduced
chondrogenesis and increased osteoblast dif-
ferentiation. Immunohistochemistry and his-
tomorphometry were used to examine the
differentiation of mesenchymal cells in the
5d calluses. (A and B) Type IIa collagen and
(C and D) Sox9 expression were evaluated
to determine areas of neochondrogenesis,
whereas (E and F) osteocalcin and (G and H)
osterix expression were used to indicate areas
of new bone formation (magniﬁcation bar =
100 mm). Positivestaining is either brown(A)
or red (C, E, and G). Blue staining in C, E,
and G represents DAPI-stained nuclei. B,
bone; C, callus tissue; F, fracture. Values are
mean± SE of WT (n = 13) and TSP2-null (n =
12) mice. *Signiﬁcantly different from WT;
p < 0.05. (I) RNA was extracted from day 5
calluses and gene expression was evaluated
using quantitative real-time PCR. Values are
mean ± SE of fold-change in TSP2-null (n =
6) compared with WT mice (n = 5); *DCT
signiﬁcantly different from WT (p < 0.05).
TSP2 AND FRACTURE HEALING 1051and overexpression of TSP prevents tumorigenesis in a
number of tissues.
(39) Furthermore, in wound healing
(18)
and tissue ischemia,
(19) an absence of TSP2 alters healing
through an increase in vascularity. Although TSP1 and
TSP2 show considerable homology, data suggest that the
TSP1 and TSP2 effects on endothelial cells is different.
Whereas TSP1 requires binding to CD36 and activation of
downstream kinases to induce apoptosis,
(40) TSP2 seems to
regulate endothelial cell proliferation through a non–
CD36-meditated mechanism that requires VLDLR.
(20,21)
A variety of earlier studies have shown a link between
angiogenesis and fracture healing. Inhibition of angiogen-
esis has been shown to cause a decrease in callus miner-
alization and callus volume.
(5,41) In contrast, treatment of
fracture calluses with an adenoviral vector carrying a
construct encoding VEGFA leading to more vascularity
resulted in a reduced amount of cartilage at 2 wk after
fracture
(42)—a phenotype similar to that seen with TSP2-
null mice. Indeed, levels of the direct transcriptional tar-
gets of Hif, VEGFA, and Glut-1
(33) were signiﬁcantly re-
duced in TSP2-null mice.
It is likely that an increase in Hif1a in oxygen-depleted
tissues impacts chondrogenic and osteogenic differentiation.
Increased activation of HIF1a increases the differentiation
of mesenchymal progenitors to chondrocytes,
(32,43) and Hif1
directly regulates Sox9 activity.
(44) Conversely, increased
HIF decreases markers of osteoblast differentiation in vi-
tro.
(45) Thus, in the absence of TSP2 when there is higher
vascularity,oxygentension isincreased,andHif1a levelsare
reduced, favoring osteogenesis.
Although alterations in vascularization and oxemia offer
a reasonable explanation for the TSP2-null fracture callus
phenotype, an absence of TSP2 could be inﬂuencing frac-
ture phenotype through at least two other mechanisms.
Increased proliferation of mesenchymal cells in the callus
could have a negative inﬂuence on chondrogenic differ-
entiation because, to undergo chondrogenic differentia-
tion, cells must ﬁrst exit the cell cycle.
(46–48) It is likely that
TSP2-null cell proliferation does account for the 20% in-
crease in callus size at day 5 and the alteration in the width-
length ratio observed at day 10. Second, it is possible that
the mesenchymal cells that are recruited into the fracture
site of the TSP2-null mice are phenotypically different than
the cells of the WT. For example, TSP2-null mice have an
increase in marrow CFU-F
(16); thus, marrow could make a
greater contribution to the healing in TSP2-null than WT
mice. These alternative explanations can not be ruled out
at this time and need to be further studied in models where
proliferation of cells is manipulated and by studying earlier
time points after fracture in which cell origin can be better
discerned.
Surprisingly, despite the signiﬁcant alterations in callus
bone and cartilage after 10 days of healing, we did not
detect any changes in the biomechanical properties. Be-
cause the biomechanical properties of the healing construct
can be attributed both to density and to the amount of
tissue, it is plausible that the biomechanical advantage of a
higher volume of bone in TSP2-null mice is offset by the
decrease in TMD at 10 days. In contrast to these results, the
energy to failure was signiﬁcantly lower in TSP2-null mice
after 20 days of healing, whereas the TMD was not dif-
ferent. These results are likely attributable to the decrease
in the volume fraction of bone present in the calluses of
TSP2-null mice at 20 days. Interestingly, this may suggest
that a ﬂorid chondrogenic response provides for a mechani-
cally advantageous callus.
FIG. 6. TSP2-null fractures show increased
angiogenesis and a reduction in markers as-
sociated with HIF1-a activity. (A and B)
Blood vessel density was determined by
counting the total number of vWF-positive
vessels in the callus (arrows). (B) Blood
vessel density is 75% greater in the callus
of TSP2-null mice compared with WT mice.
(C and D) VEGF expression in calluses was
evaluated using immunoﬂuorescence (mag-
niﬁcation bar = 100 mm). B, bone; C, callus
tissue; F, fracture. Values are mean ± SE of
WT (n = 13) and TSP2-null (n = 12) mice.
*Signiﬁcantly different from WT (p < 0.05).
(E) RNA was extracted from day 5 calluses
and gene expression was evaluated using quanti-
tative real-time PCR. Values are mean ± SE
of fold-change in TSP2-null (n =6 )c o m -
p a r e dw i t hW Tm i c e( n =5 ) .* DCT signiﬁcantly
different from WT (p < 0.05).
1052 TAYLOR ET AL.The high expression of TSP2 early in fracture healing
(Fig. 2) and the phenotype of TSP2-null fractures suggests
that TSP2 plays an important role in the regulation of early
fracture mesenchyme. Multiple factors must act in con-
cert to inﬂuence the fate of early callus mesenchyme. By
regulating the balance of proangiogenic factors and factors
that regulate mesenchymal cell proliferation and differen-
tiation, we may be able to better inﬂuence fracture healing
clinically. Indeed, as proof-of-principle, by delivering TSP2
adenovirus, we were effectively able to generate a more
chondrogenic fracture callus.
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